Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 120Lymphoma 90Lymphoma, Large B-Cell, Diffuse 79Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Burkitt Lymphoma 31Multiple Myeloma 26Lymphoma, Non-Hodgkin 26Lymphoma, Follicular 26Leukemia 26Hodgkin Disease 24Lymphoma, Mantle-Cell 18Neoplasms 16Lymphoma, T-Cell, Peripheral 16Lymphoma, B-Cell 14Lymphoma, Large-Cell, Immunoblastic 12Lymphoma, Large-Cell, Anaplastic 11Dendritic Cell Sarcoma, Interdigitating 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Recurrence 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Lymphocytic, Chronic, B-Cell 8Neoplasms, Plasma Cell 7Neoplasm Metastasis 7Waldenstrom Macroglobulinemia 6Primary Myelofibrosis 6Lymphoma, T-Cell 6Immunoblastic Lymphadenopathy 6HIV Infections 5Graft vs Host Disease 5Blast Crisis 5

Interventions

Amifostine 10Cisplatin 8Radiotherapy 7Etoposide 6Cyclophosphamide 4Carboplatin 4Paclitaxel 3pegfilgrastim 2camrelizumab 2apatinib 2Mitoxantrone 2Filgrastim 2Drug Therapy 2Cytarabine 2sodium thiosulfate 1sargramostim 1pazopanib 1icotinib 1glucarpidase 1etoposide phosphate 1denileukin diftitox 1Vitamin E 1Triptorelin Pamoate 1Tocopherols 1Thiotepa 1Tegafur 1Taxes 1Surgical Procedures, Operative 1Silymarin 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Drug-Related Side Effects and Adverse Reactions × Prednisone × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡